Notably, TMEM127 mutations or reduced expression are also seen at low frequencies in a number of other tumor types (e.g. endometrial, liver, breast, kidney, ovarian cancers; Tate et al., 2019) where TMEM127 contributions have not yet been specifically recognized, suggesting that aberrant accumulation and activation of growth factor receptors could also impact these tumors. Here, TMEM127 is linked to ovarian carcinoma.